Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) was the target of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 528,200 shares, a decrease of 18.1% from the October 15th total of 644,700 shares. Approximately 2.1% of the company’s shares are short sold. Based on an average trading volume of 159,300 shares, the short-interest ratio is currently 3.3 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. StemPoint Capital LP lifted its holdings in shares of Vistagen Therapeutics by 3.3% in the 1st quarter. StemPoint Capital LP now owns 1,848,582 shares of the company’s stock worth $9,292,000 after purchasing an additional 58,400 shares during the last quarter. Valence8 US LP acquired a new stake in shares of Vistagen Therapeutics in the third quarter valued at $103,000. Acadian Asset Management LLC bought a new stake in Vistagen Therapeutics during the first quarter worth approximately $169,000. Blair William & Co. IL increased its stake in Vistagen Therapeutics by 29.2% in the 2nd quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock worth $308,000 after purchasing an additional 20,000 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Vistagen Therapeutics by 49.1% in the 2nd quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after acquiring an additional 9,984 shares in the last quarter. 78.39% of the stock is owned by institutional investors and hedge funds.

Vistagen Therapeutics Price Performance

NASDAQ:VTGN opened at $2.66 on Friday. Vistagen Therapeutics has a 1-year low of $2.65 and a 1-year high of $5.86. The firm has a 50-day moving average of $3.05 and a two-hundred day moving average of $3.51.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%. The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.30 million. During the same period last year, the firm earned ($0.94) earnings per share. On average, research analysts expect that Vistagen Therapeutics will post -1.85 EPS for the current year.

Analyst Ratings Changes

Separately, William Blair raised shares of Vistagen Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.